Search results
Results from the WOW.Com Content Network
After loss of exclusivity and generic launch the originator brand normally continues to hold at least some market share as either some doctors continue to prescribe the brand or as the originator equalises sales prices against the generic. [27] [28] Generic, brand and reimbursement (drug tariff) price decay. Branded manufactures may build ...
Drug Price Competition and Patent Term Restoration Act; Long title: An Act to amend the Federal Food, Drug, and Cosmetic Act to revise the procedures for new drug applications, to amend title 35, United States Code, to authorize the extension of the patents for certain regulated products, and for other purposes.
Roche was a brand-name pharmaceutical company which made and sold a sleep aid Dalmane, the active ingredient of which Flurazepam was protected by patent. [1] Before patent expiration, Bolar used the patented chemical in experiments to determine if its generic product was bioequivalent to Dalmane in order to obtain FDA approval for its generic ...
With patents on many blockbuster drugs about to expire, an estimated $250 billion in sales are at ... Bristol-Myers Squibb is facing 2012 patent expirations for two of its three top sellers ...
The drug accounts for around half of the company's total sales and was one of its main growth drivers last quarter. While most Patent Expirations AbbVie Investors Need to Watch
The upside to better patient care is unlimited. Unfortunately, from a business perspective, the upside potential of exclusively being able to marketing life-enhancing drugs is finite. 2012 turned ...
Many of these petitions are filed near the date of patent expiration, effectively limiting potential competition for another 150 days. “Authorized generics": an authorized generic is exactly the same as the brand name drug, but marketed without the brand name on the label.
Legalwise, generic counterparts have to wait for at least 2 decades for patent expiration to sell a copy . This system is said to aim for a balance between gaining public access to generic drugs and encouraging drug research and development. [23]